Approximately 15–25% of Caucasians and 40–55% of East Asian patients with lung cancer carry EGFR mutations, and the evolution of tyrosine kinase inhibitors (TKIs) targeting EGFR mutations has improved progression-free survival (PFS) and overall survival (OS) in these patients [3,4,5]. Here, EGFR is linked to lung carcinoma.